Zirgan (ganciclovir) PDUFA Date (Bausch And Lomb)
FDA PDUFA decision date for Zirgan (ganciclovir) is January 20, 2026. Developed by Bausch And Lomb. Indication: Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Nucleoside Analog Antiviral [EPC]. Current status: Approved.
Indication
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Nucleoside Analog Antiviral [EPC]
Regulatory details
- Company: Bausch And Lomb
- Therapeutic area: Infectious Disease
- Application type: sNDA
- Review type: Standard
- PDUFA date: 2026-01-20
- Outcome: Approved